3/29
08:38 pm
kymr
Does Positive KT-621 Atopic Dermatitis Data Change The Bull Case For Kymera Therapeutics (KYMR)? [Yahoo! Finance]
Low
Report
Does Positive KT-621 Atopic Dermatitis Data Change The Bull Case For Kymera Therapeutics (KYMR)? [Yahoo! Finance]
3/28
11:12 am
kymr
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
Low
Report
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
3/28
11:00 am
kymr
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Low
Report
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
3/16
10:58 am
kymr
Kymera Therapeutics (KYMR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Low
Report
Kymera Therapeutics (KYMR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
3/14
05:36 pm
kymr
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside [Yahoo! Finance]
Low
Report
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside [Yahoo! Finance]
3/12
01:21 pm
kymr
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/10
07:08 am
kymr
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
Low
Report
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
3/10
07:00 am
kymr
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
Low
Report
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
3/9
10:47 pm
kymr
Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss [Yahoo! Finance]
Low
Report
Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss [Yahoo! Finance]
3/7
02:59 am
kymr
Low
Report
3/3
02:22 pm
kymr
Kymera Therapeutics (KYMR) had its price target raised by UBS Group AG from $90.00 to $128.00. They now have a "buy" rating on the stock.
Low
Report
Kymera Therapeutics (KYMR) had its price target raised by UBS Group AG from $90.00 to $128.00. They now have a "buy" rating on the stock.
3/2
01:53 pm
kymr
Kymera Therapeutics (KYMR) had its price target raised by Citigroup Inc. from $110.00 to $120.00. They now have a "buy" rating on the stock.
Low
Report
Kymera Therapeutics (KYMR) had its price target raised by Citigroup Inc. from $110.00 to $120.00. They now have a "buy" rating on the stock.
3/2
09:27 am
kymr
Kymera Therapeutics (KYMR) had its price target raised by Stephens from $95.00 to $100.00. They now have an "overweight" rating on the stock.
Low
Report
Kymera Therapeutics (KYMR) had its price target raised by Stephens from $95.00 to $100.00. They now have an "overweight" rating on the stock.
2/28
03:42 pm
kymr
The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans [Yahoo! Finance]
Low
Report
The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans [Yahoo! Finance]
2/28
01:40 pm
kymr
Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 [Yahoo! Finance]
Low
Report
Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 [Yahoo! Finance]
2/27
09:16 am
kymr
Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler [Yahoo! Finance]
Medium
Report
Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler [Yahoo! Finance]
2/26
05:33 pm
kymr
Kymera Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Kymera Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
05:03 pm
kymr
Kymera Therapeutics (KYMR) had its "overweight" rating reaffirmed by Morgan Stanley.
Medium
Report
Kymera Therapeutics (KYMR) had its "overweight" rating reaffirmed by Morgan Stanley.
2/26
02:11 pm
kymr
Kymera Therapeutics (KYMR) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Medium
Report
Kymera Therapeutics (KYMR) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
2/26
01:58 pm
kymr
Kymera Therapeutics (KYMR) had its price target lowered by BTIG Research from $138.00 to $134.00. They now have a "buy" rating on the stock.
Medium
Report
Kymera Therapeutics (KYMR) had its price target lowered by BTIG Research from $138.00 to $134.00. They now have a "buy" rating on the stock.
2/26
11:52 am
kymr
Kymera Therapeutics (KYMR) had its price target raised by Piper Sandler from $125.00 to $140.00. They now have an "overweight" rating on the stock.
Medium
Report
Kymera Therapeutics (KYMR) had its price target raised by Piper Sandler from $125.00 to $140.00. They now have an "overweight" rating on the stock.
2/26
07:32 am
kymr
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]
High
Report
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]
2/26
07:00 am
kymr
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Medium
Report
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
2/24
07:00 am
kymr
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Low
Report
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
2/19
07:34 am
kymr
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 [Yahoo! Finance]
Low
Report
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 [Yahoo! Finance]